Cardiovascular outcomes of glucagon-like peptide-1 receptor agonists: A systematic review
Researchers evaluated cardiovascular outcome trials for glucagon-like peptide-1 receptor agonists (GLP1RAs) in patients with type 2 diabetes, overweight/obesity with atherosclerotic cardiovascular disease, and obesity with heart failure with preserved ejection fraction. The review found that GLP1RA therapy consistently reduced major adverse cardiovascular events in patients with type 2 diabetes. Weekly subcutaneous semaglutide lowered the risk of major adverse cardiovascular events in patients with overweight/obesity and atherosclerotic cardiovascular disease without type 2 diabetes. Tirzepatide lowered the composite endpoint of adverse heart failure events and cardiovascular death in patients with obesity and heart failure with preserved ejection fraction.
What to check after reading
This systematic review summarizes evidence for cardiovascular benefits of GLP1RAs, noting consistent reduction in major adverse cardiovascular events in type 2 diabetes patients but uncertain effects on cardiovascular and all-cause death.
Source
Calendar dates show when a case was added or scheduled. For event dates, check the original source.